A retrospective review of changes and challenges in the use of antiseizure medicines in Dravet syndrome in Norway
Open Access
- 26 June 2020
- journal article
- review article
- Published by Wiley in Epilepsia Open
- Vol. 5 (3) , 432-441
Abstract
Objective: Dravet syndrome is a developmental and epileptic encephalopathy characterized by severe and drug‐resistant seizures in early childhood, followed by developmental delay. The purpose of this study was to investigate aspects of pharmacological treatment of Norwegian patients with Dravet syndrome, focusing on the use of antiseizure medicines (ASMs) and identifying treatment challenges.Methods: Patients were identified through medical registries at the National Center for Epilepsy in Norway and National Center for Rare Epilepsy Related Disorders during 2008‐2018. Additional clinical data were obtained from medical records and laboratory request forms.Results: We identified 53 patients with Dravet syndrome, 30/23 males/females, aged 2‐50 years. The majority of patients with known seizure frequency experienced frequent seizures, 80% (n = 35/44). Only two patients were seizure‐free. Valproate (n = 48), clobazam (n = 45), levetiracetam (n = 30), and stiripentol (n = 38) were most commonly used, previous or current use. More than one‐third (n = 20) had tried sodium channel blockers (including lamotrigine), but these drugs were used less during the last decade. Polytherapy was common, 81% (n = 43) used two or more ASMs, and eight of these patients used 4‐5 drugs (15%). Several challenges were identified: high seizure frequency, comorbidities, treatment changes with a wide range of ASMs, common use of oral gastro‐tubes, extensive polypharmacy, and drug interactions.Significance: The use of ASMs has changed over the last decade, in accordance with updated international recommendations. Various treatment challenges were identified. This vulnerable group of patients needs close follow‐up for an optimal treatment outcome.Keywords
This publication has 35 references indexed in Scilit:
- 30 years of second-generation antiseizure medications: impact and future perspectivesThe Lancet Neurology, 2020
- Therapeutic drug monitoring of antiepileptic drugs: current status and future prospectsExpert Opinion on Drug Metabolism & Toxicology, 2020
- SCN1A/NaV1.1 channelopathies: Mechanisms in expression systems, animal models, and human iPSC modelsEpilepsia, 2019
- Treatment Strategies for Dravet SyndromeCNS Drugs, 2018
- Antiepileptic drugs for the treatment of infants with severe myoclonic epilepsyCochrane Database of Systematic Reviews, 2017
- Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus PanelPediatric Neurology, 2017
- From genotype to phenotype in Dravet diseaseSeizure: European Journal of Epilepsy, 2017
- Treatment of Dravet SyndromeCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2016
- Dravet syndrome—From epileptic encephalopathy to channelopathyEpilepsia, 2014
- The core Dravet syndrome phenotypeEpilepsia, 2011